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Background:To investigate the role of nonsurgical treatment for 
early-stage esophageal cancer, we compared the outcomes of local 
therapy to esophagectomy, using a large, national database.
Methods:Five-year cancer-specific and overall survival (OS) of 
patients, with T1N0M0 squamous cell or adenocarcinoma of the mid 
or distal esophagus treated with either surgery or local therapy, with 
ablative and/or excision techniques, in the Surveillance Epidemiology 
and End Results cancer registry from 1998 to 2008, were compared 
using the Kaplan–Meier approach, and multivariable and propensity-
score adjusted Cox proportional hazard, and competing risk models.
Results:Of 1458 patients with T1N0 esophageal cancer, 1204 (83%) 
had surgery and 254 (17%) had local therapy only. The use of local 
therapy increased significantly from 8.1% in 1998 to 24.1% in 2008 
(p < 0.001). The 5-year OS after local excisional therapy and surgery 
was not significantly different (55.5% versus 64.1% respectively, 
p = 0.07), and 5-year cancer-specific survival (CSS) also did not 
differ (81.7% versus 75.8%, p = 0.10). However, after propensity-
score adjustment, CSS was better for patients who underwent local 
therapy compared with those who underwent surgery (hazard ratio: 
0.46, 95% confidence interval: 0.27–0.77, p = 0.003), whereas OS 
remained similar.
Conclusion:The use of local therapy for T1N0 esophageal cancers 
increased significantly from 1998 to 2008. Compared with those 
treated with esophagectomy, patients treated with local therapy had 
similar OS but improved CSS, indicating a higher chance of dying 
from other causes. Further studies are needed to confirm the onco-
logic efficacy of local therapy when used in patients whose lifespans 
are not limited by conditions other than esophageal cancer.
Key Words: Local therapy, Esophagectomy, Esophageal cancer, 
Adenocarcinoma, Squamous cell cancer.
(J Thorac Oncol. 2013;8: 796-802)
The prognosis for patients treated for intra- and submucosal esophageal cancers is significantly better than the prognosis 
for other patients found to have esophageal cancer, even those 
found in other relatively early-stage diseases.1 Historically, 
esophagectomy has been demonstrated to be oncologically 
efficacious; however, despite improvement over time, surgery 
is still associated with considerable morbidity and mortal-
ity.2–8 Local treatments with modalities, such as endoscopic 
mucosal resection, radiofrequency ablation, cryotherapy, and 
photodynamic therapy have shown potential for providing 
effective cancer treatment with much less treatment-related 
morbidity.9–20 However, most reports related to these thera-
pies involve relatively small clinical trials or single-institution 
retrospective reviews with limited long-term follow-up. We 
sought to investigate treatment trends of local therapy use for 
T1N0 esophageal cancer, using the population-based, national 
Surveillance Epidemiology and End Results (SEER) cancer 
registry. To evaluate the efficacy of local therapy compared 
with esophagectomy, we also sought to test the hypothesis that 
patients with stage T1N0M0 esophageal cancer in the SEER 
database from 1998 to 2008 who underwent esophagectomy 
had improved survival, compared with patients who had local 
therapy.
PATIENTS AND METHODS
Approval was obtained from the Duke University 
Institutional Review Board before conducting this 
retrospective cohort analysis using SEER data for patients 
from 1998 to 2008. SEER Stat 7.0.5 was used to extract data 
of patients who were 18 years of age or older, with cancer of 
the mid or lower esophagus. Patients were primarily identified 
through the SEER Site Recode using the term esophagus. The 
variable Histologic Type ICD-O-3 (International Classification 
of Diseases for Oncology, 3rd edition) was used to restrict 
the study cohort to patients with either squamous cell cancer 
(codes 8050–8089), or adenocarcinomas (codes 8140–8389). 
To restrict the cohort to patients with T1N0M0 tumors, the 
tumor, node, metastasis (TNM) stage was either directly 
extracted from the SEER database or manually recoded, using 
available SEER variables. The 6th edition of the American 
Joint Committee on Cancer staging manual served as the basis 
for this recoding.21 Patients with unknown or other tumor, 
node, metastasis stages were excluded from the analysis.
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The primary outcome was 5-year cancer-specific sur-
vival (CSS) and overall survival (OS), measured in months. 
Patients alive at the last available follow-up date in SEER 
were right censored at this date, in the survival analysis. 
The following additional data of patient characteristics were 
extracted from the data set: age, sex, race (white, black, other/
unknown), marital status (married, other/unknown), and cause 
of death (alive, esophagus, other cause of death). In addition, 
data on tumor grade (well/moderate, poor/undifferentiated, 
unknown), tumor location (mid or distal esophagus), and 
histology (adenocarcinoma, squamous cell) were collected. 
On the basis of the treatment information available in SEER, 
we defined two distinct treatment groups: esophagectomy 
and local therapy. All other patients were excluded from the 
analysis.
Detailed information on the depth of invasion of T1 
tumors was recorded, starting in 2004, which allowed fur-
ther stratification of T1 tumors into those that did not invade 
the submucosa (T1a) and those that invaded the submucosa 
(T1b), according to the newer, 7th edition of the American 
Joint Committee on Cancer staging system.22 Because the risk 
of lymph-node metastases increases to 26% when the sub-
mucosa is involved, local therapy with endoscopic mucosal 
resection as curative intent has been proposed as indicated for 
T1 tumors that do not invade the submucosa.9,23,24 Therefore, 
subgroup survival analyses were performed for patients with 
T1a tumors.
Statistical Analysis
Comparisons of patient characteristics among the two 
treatment groups were performed, using χ2 test for categorical 
(frequency, percentages), and two-sample, unpaired t test for 
continuous variables (mean, standard deviations), respectively. 
To assess early versus late treatment among patients undergo-
ing local therapy, patients were grouped in two time periods; 
early, from 1998 to 2003 and late, from 2004 to 2008. To com-
pare treatment trends over time between patients undergoing 
esophagectomy and patients undergoing local therapy, multi-
variable adjusted logistic regression models were calculated 
whereas year of operation was the main predictor. Adjustment 
was performed for sex, age at diagnosis, race, marital status, 
tumor grade, tumor localization, radiation therapy use, and 
histology.
CSS was assessed focusing on patients with a cause of 
death due to esophageal cancer while all other deaths were 
right censored. Meanwhile, OS included all deaths from any 
cause in the follow-up period, though patients alive were 
right censored. Because staging in patients with local tumor 
destruction cannot be assessed with pathological examina-
tion, these patients were excluded from the survival analysis 
so that clinical overstaging or understaging in these patients 
would not bias survival results. To compare CSS and OS 
among the treatment groups, survival curves were initially 
constructed according to the Kaplan–Meier approach and 
compared using the log-rank test. Subsequently, unadjusted, 
multivariable, and propensity-score adjusted Cox propor-
tional hazard models for OS and competing-risks regres-
sion models for CSS were calculated. Results are presented 
as hazard ratios (HR) and 95% confidence intervals (CIs). 
Adjustment in the survival analyses was performed for the 
following covariates: sex, age, race, marital status, tumor 
grade, tumor location, histology, and year of diagnosis 
(5 groups). The propensity score was calculated based on a 
logistic regression model, in which esophagectomy and local 
therapy were shown representing the outcome, and the fol-
lowing characteristics were used as covariates in the propen-
sity score calculation: sex, age, race, marital status, tumor 
grade (unknowns were included as additional category), 
tumor location, histology, and year of diagnosis (5 groups). In 
the propensity-score adjusted survival models, the propensity 
score representing receipt of esophagectomy or local therapy 
was added as an additional potential confounder. To account 
for immortal time bias with regard to receipt of esophagec-
tomy and radiation therapy after diagnosis, we performed two 
sets of landmark studies in the survival analyses of left-trun-
cating patients, who survived less than 3 or 6 months.25 These 
additional analyses allowed further decrease in the selection 
bias by excluding patients with short-term adverse periopera-
tive mortality or life-limiting comorbidities.
All statistical analyses were performed using STATA/
SE version 11.2 (Stata Corporation, College Station, TX) and 
R version 2.15.1 (R Foundation for Statistical Computing, 
Vienna, Austria); the significance level alpha set at 0.05, and 
two-sided p values calculated for all analyses.
RESULTS
A total of 1458 patients with T1N0M0 esophageal can-
cer of the mid and lower esophagus were identified in the 
SEER cancer registry, during the study period from 1998 to 
2008: Of these, 1204 (83%) were treated with surgery and 
254 (17%) had local therapy only. Detailed patient and tumor 
characteristics stratified by treatment group are presented 
in Table 1. Compared with patients who underwent surgery, 
patients treated with local therapy were significantly older, 
more likely to be female, more likely to have a mid esopha-
geal cancer, and less likely to have received radiation therapy. 
Table 2 shows the specific types of local therapy used. The 
usual modality used was that of local tumor excision.
There was a significant increase in local treatment use 
from 8.1% in 1998 to 24.1% in 2008 (Fig. 1). This trend held 
true after multivariable adjustment with an odds ratio of 1.18 
per year (CI: 1.11–1.25, p < 0.001). There was no difference 
in patient and tumor characteristics when comparing patients 
undergoing local therapy during the early and later time period 
(data not shown).
The results of survival analysis comparing 
esophagectomy with local excisional therapy are shown in 
Table 3 and Figure 2. Median follow-up was 34 months for 
surgery, and 21 months for local excisional therapy (p < 
0.001), whereas mean follow-up was 40.5 months for surgery, 
and 27.3 months for local excisional therapy (p < 0.001). For 
all patients, 5-year OS was 63.2% (95% CI: 60.0–66.3) and 
5-year CSS was 76.5% (CI: 73.5–79.2). Five-year OS after 
local excisional therapy and surgery was not significantly 
different (55.5% [CI: 44.0–65.6] versus 64.1% [CI: 60.7–67.3], 
p = 0.07) as was 5-year CSS (81.7% [CI: 70.2–89.1] versus 
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75.8% [CI: 72.6–78.7], p = 0.10). However, although local 
excisional therapy did not predict any statistically significant 
difference in OS compared with surgery in both multivariable 
(HR: 0.85, CI: 0.63–1.15, p = 0.29) and propensity-score (HR: 
0.88, CI: 0.64–1.20, p = 0.42) adjustment, local excisional 
therapy did predict improved CSS compared with surgery 
in both multivariable (HR: 0.46, CI: 0.28–0.76, p = 0.002) 
and propensity-score adjusted survival analyses (HR: 0.46, 
CI: 0.27–0.77, p = 0.003).
The short-term OS after esophagectomy was similar 
to that of local excisional therapy at 1 month (esophagec-
tomy 98.6% [CI: 97.7–99.1] versus local excisional therapy 
99.5% [CI: 96.7–99.9]), 3 months (esophagectomy 96.9% 
[CI: 95.7–97.7] versus local excisional therapy 98.0% [CI: 
94.9–99.3]), and 6 months (esophagectomy 92.9% [CI: 91.2–
94.2] versus local excisional therapy 93.4% [CI: 88.9–96.1], 
p > 0.26 for all comparisons). To address potential immortal 
bias in the survival analyses, and to compare long-term out-
comes of esophagectomy and local excisional therapy, when 
short-term, presumably treatment- and comorbidity-related, 
mortality is excluded, landmark studies for CSS and OS were 
performed by applying 3- and 6-month left truncation to sur-
vival times (Table 4). These landmark studies showed similar 
findings to the nonlandmark survival analysis. Patients treated 
with local therapy continued to have better CSS in both the 
3- and 6-month truncated studies, although OS was not differ-
ent between the local excisional therapy and esophagectomy 
patients.
Subgroup Analysis for Patients 
with T1a Tumor Stage
Among patients diagnosed from 2004 to 2008, infor-
mation about T1a and T1b tumor stage was available for 764 
TABLE 1.  Patient Characteristics
Esophagectomy
(n = 1204)
Local Therapy
(n = 254) p
Age (mean, SD), yr 64.4 (10.0) 73.4 (9.7) <0.001
Female 190 (15.8%) 60 (23.6%) 0.003
Race
 White 1111 (92.3%) 240 (94.5%) 0.17
 Black 45 (3.7%) 10 (3.9%)
 Other/unknown 48 (4.0%) 4 (1.6%)
Marital status
 Married 850 (70.6%) 164 (64.6%) 0.06
 Other/unknown 354 (29.4%) 90 (35.4%)
Tumor location
 Mid esophagus 199 (16.5%) 56 (22.1%) 0.04
 Lower esophagus 1005 (83.5%) 198 (78.0%)
Tumor grade
 G1/2 (well/moderate) 649 (53.9%) 105 (41.3%) <0.001
 G3/4 (poor/undifferentiated) 342 (28.4%) 41 (16.1%)
 Unknown 213 (17.7%) 108 (42.5%)
Histology
 Squamous cell carcinoma 220 (18.3%) 38 (15.0%) 0.21
 Adenocarcinoma 984 (81.7%) 216 (85.0%)
Radiation therapy
 No radiotherapy 957 (79.5%) 217 (85.4%) 0.02
 Beam radiotherapy 242 (20.1%) 34 (13.4%)
 Unknown 5 (0.4%) 3 (1.2%)
Cause of death
 Alive 831 (69.0%) 179 (70.5%) <0.001
 Esophagus 228 (18.9%) 27 (10.6%)
 Other 145 (12.0%) 48 (18.9%)
Time period
 Early (1998–2003) 487 (40.4%) 48 (18.9%) <0.001
 Late (2004–2008) 717 (59.6%) 206 (81.1%)
SD, standard deviation.
TABLE 2.  Distribution of Local Therapies
Procedure
Overall  
n (%)
Early  
(1998–2003); 
 n (%)
Late  
(2004–2008); 
n (%)
Local tumor destruction
 Photodynamic therapy 22 (8.7) 8 (16.7) 14 (6.8)
 Electrocautery 2 (0.8) 0 2 (1.0)
 Cryosurgery 4 (1.6) 0 4 (1.9)
 Laser 8 (3.2) 2 (4.2) 6 (2.9)
 NOS 2 (0.8) 0 2 (1.0)
Local tumor excision
 Polypectomy 23 (9.1) 3 (6.3) 20 (9.7)
 Excisional biopsy 96 (37.8) 19 (39.6) 77 (37.4)
 Laser excision 2 (0.8) 0 2 (1.0)
 NOS 51 (20.1) 6 (12.5) 45 (21.8)
Combined local tumor  
destruction and excision
44 (17.3) 10 (20.8) 34 (16.5)
NOS, not otherwise specified.
FIGURE 1.  Change of use of esophagectomy and local 
therapy from 1998 to 2008. Straight line: esophagectomy. 
Discontinuous line: local therapy. Multivariable adjusted  
p for trend < 0.001 (odds ratio per year: 1.18, 95% confi-
dence interval: 1.11–1.25).
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patients (82.8%). Of those, 436 patients (57.1%) had a T1a 
esophageal cancer, whereas 302 patients (69.3%) underwent 
esophagectomy, and 134 patients (30.7%) local therapy. 
Among patients with T1b tumor stage (n = 328, 42.9%), 296 
patients (90.2%) underwent surgery and 32 patients (9.8%) 
underwent local therapy. Fifteen patients (3.4%) and 5 patients 
(1.5%) with T1a and T1b, respectively, who underwent local 
tumor destruction, were excluded from survival analysis. For 
patients with T1a tumors, survival for esophagectomy (2-year 
CSS: 92.3%, CI: 88.1–95.1; 2-year OS: 86.1, CI: 81.0–89.8), 
and local excisional therapy (2-year CSS: 92.6%, CI: 84.0–
96.6; 2-year OS: 84.9, CI: 75.7–90.8) did not differ, even after 
multivariable (HR for CSS: 0.55, CI: 0.25–1.21, p = 0.14; HR 
for OS: 1.01, CI: 0.57–1.81, p = 0.96) and propensity-score 
adjustment (HR for CSS: 0.56, CI: 0.27–1.19, p = 0.13; HR 
for OS: 1.02, CI: 0.56–1.85, p = 0.94) (Fig. 3A). Kaplan–
Meier survival curves for patients with T1b tumors are shown 
in Figure 3B, although similar comparative survival analyses 
were not performed because of the smaller numbers (n = 27) 
of T1b tumors treated with local excisional therapy.
DISCUSSION
In this study using the SEER database, which is the larg-
est U.S. population-based cancer registry, we found that local 
therapy was increasingly used for the treatment of T1N0M0 
esophageal cancer over the period 1998–2008, with a con-
comitant decrease in the use of esophagectomy. OS after local 
therapy was similar to OS after esophagectomy, and included 
short-term follow-up of 1 month, 3 months, and 6 months 
after diagnosis. However, patients treated with local therapy 
had better CSS.
These results are encouraging and show the potential of 
utilizing local therapy as an effective oncologic treatment in 
patients with early-stage esophageal cancer. Considering the 
recovery and potential morbidity associated with the alter-
native treatment of esophagectomy, local therapy is a very 
attractive therapeutic option. However, some caution should 
be exercised before generalizing these results as a support 
that all patients with superficial esophageal cancer should be 
treated with local therapy. The fact that patients treated with 
local therapy have similar OS but better CSS than patients 
TABLE 3.  Cancer-Specific and Overall Survival for Patients Undergoing Esophagectomy and Local Therapy
5-Yr Survival 
(95% CI) p
Unadjusted HR 
(95% CI) p
Multivariable Adjusted 
HR (95% CI) p
Propensity-Score 
Adjusted HR (95% CI) p
Cancer-specific survival
 Overall treatment 76.5 (73.5–79.2)
  Esophagectomy 75.8 (72.6–78.7) 0.1 Ref.
0.62 (0.40–0.98)
0.04 Ref.
0.46 (0.28–0.76)
0.002 Ref. 
0.46 (0.27–0.77)
0.003
  Local therapya 81.7 (70.2–89.1)
Overall survival
 Overall treatment 63.2 (60.0–66.3)
  Esophagectomy 64.1 (60.7–67.3) 0.07 Ref. 
1.28 (0.98–1.68)
0.07 Ref. 
0.85 (0.63–1.15)
0.29 Ref. 
0.88 (0.64–1.20)
0.42
  Local therapya 55.5 (44.0–65.6)
aPatients with local destruction only were excluded from this analysis.
HR, hazard ratio; CI, confidence interval.
FIGURE 2.  Five-year CSS and OS 
comparing esophagectomy and local 
therapy. Number of patients at risk 
at time 0 (esophagectomy: n = 1204; 
local therapy: n = 254). Log-rank test 
for CSS: p = 0.10, and for OS: p = 
0.07. CSS, cancer-spefic survival; OS, 
overall survival.
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TABLE 4.  Landmark Analysis with Left Truncation for 3 and 6 Months—Cancer-Specific and Overall Survival
Left Truncation for 3 Mo Left Truncation for 6 Mo
Multivariable  
adjusted HR  
(95% CI) p
Propensity-score 
adjusted HR  
(95% CI) p
Multivariable  
adjusted HR  
(95% CI) p
Propensity-score 
adjusted HR  
(95% CI) p
Cancer-specific survival
 Esophagectomy  
 Local therapya
Ref. 
0.53 (0.32–0.89)
0.02 Ref. 
0.53 (0.32–0.90)
0.02 Ref. 
0.52 (0.30–0.91)
0.02 Ref. 
0.53 (0.30–0.94)
0.03
Overall survival
 Espohagectomy  
 Local therapya
Ref. 
0.90 (0.66–1.23)
0.52 Ref. 
0.94 (0.68–1.30)
0.69 Ref. 
0.94 (0.67–1.32)
0.73 Ref. 
0.99 (0.70–1.41)
0.96
aPatients with local destruction only were excluded from this analysis.
HR, hazard ratio; CI, confidence interval.
FIGURE 3. A, CSS and OS compar-
ing esophagectomy and local therapy 
in T1a tumor subgroups. Number 
of patients at risk at time 0 (esopha-
gectomy: n = 302; local therapy: n = 
119). Log-rank test for CSS: p = 0.93, 
and for OS: p = 0.31. B, CSS and OS 
comparing esophagectomy and local 
therapy in T1b tumor subgroups. 
Number of patients at risk at time 
0 (esophagectomy: n = 296; local 
therapy: n = 27). Log-rank test for 
CSS: p = 0.07, and for OS: p = 0.80. 
CSS, cancer-specific survival; OS, 
overall survival.
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undergoing esophageal resection demonstrates that patients 
treated with local therapy are dying from causes other than 
esophageal cancer at a much higher rate than patients treated 
with esophagectomy. Although SEER does not record data 
regarding comorbidities, patients selected to receive local ther-
apy may have been more likely than esophagectomy patients 
to have had significant other medical conditions that either 
made them medically ineligible for surgery or were more 
immediately life-threatening than early-stage esophageal can-
cer. This possibility is supported by the observation that 1-, 3-, 
and 6-month survival after local therapy seems quite similar 
to that seen after esophagectomy, despite the general thinking 
that local therapies have less procedure-related mortality. This 
possibility is also further supported by the landmark analy-
sis. Given that the results of the survival comparison between 
treatment modalities did not change in the landmark analysis 
with both 3- and 6-month truncation, the effects on survival 
on what would be expected to be increased peritreatment mor-
tality in the esophagectomy group, seems to be offset by the 
presumably nonprocedure-related mortality in the local ther-
apy group.
Therefore, although results after local therapy seem 
similar to esophagectomy in this study, continued investigation 
is necessary before it is possible to conclude that oncologic 
outcomes are truly similar between the two approaches. The 
patients treated with local therapy in this study may have been 
dying of other causes before residual or recurrent esophageal 
cancer could occur or lead to mortality. Studies of local therapy 
with longer follow-up and younger patients who do not have 
other significant, potentially life-limiting medical conditions 
are needed to truly demonstrate that local therapy does not have 
a higher rate of disease recurrence compared to esophagec-
tomy. Further observational studies, and perhaps even multi-
institutional, randomized, controlled trials are recommended 
to confirm the oncologic efficacy of local therapy. Until then, 
patients treated with local therapy should have close surveil-
lance to evaluate treatment failures and disease recurrence.
Despite the high mortality typically associated with 
esophagectomy, OS after esophageal cancer diagnosis 1, 3, 
and 6 months after esophagectomy in this study was 98.6%, 
96.9%, and 92.9%, respectively. The corresponding mortality 
rates of 1.4%, 3.1%, and 7.1%, respectively, are generally bet-
ter than those seen in multi-institutional studies or registries, 
and more in line with results reported by specialized cen-
ters.3–5,8 Data from this study do not allow investigation into 
the reason for this lower-than-expected mortality. A possible 
explanation for this finding is that esophagectomy for early-
stage disease, when there is no bulky tumor that increases 
the difficulty of resection, and where patients are less likely 
to have been given induction therapy, has significantly bet-
ter results than when surgery is performed for more advanced 
tumors. Even if mortality is not significantly different in this 
study, it is important to acknowledge that esophagectomy 
likely has significantly higher peritreatment morbidity than 
local therapy. In addition, esophagectomy may be associated 
with lifelong alterations in eating habits. To some patients, 
these potential short-term and long-term effects on lifestyle 
may be worth the trade-off given the potential slightly higher 
disease recurrence rates involved.
Given that our data suggest that local treatment is at least 
not inferior to surgery, the use of local therapy may continue 
to increase for several reasons. First, the techniques of both 
local resection and local tissue destruction may improve and 
allow more patients to be adequately treated with these modal-
ities. Second, the increasing percentage of older patients in 
society may result in more patients being found to have early-
stage esophageal cancer but also considered marginal candi-
dates for esophageal resection. Third, the encouraging results 
associated with local therapy may lead to its increased use in 
younger and healthier patients, who also would be considered 
good surgical candidates. However, the costs associated with 
long-term surveillance must be considered when local therapy 
is progressively used for younger and healthier patients.
Advantages of the use of SEER data for this analysis 
include its population-based nature, with volume sufficient 
to enable subgroup analysis. However, SEER does also have 
some inherent limitations. First, data regarding chemotherapy 
administration are lacking. However, chemotherapy is not rec-
ommended for this stage of esophageal cancer,24 and there-
fore this limitation is not likely to be significant in this study. 
However, the exact influence of chemotherapy in this patient 
cohort cannot be evaluated. Second, as described above, there 
is a lack of data regarding patient comorbidities, which allow 
specific evaluation on the importance of comorbidities on 
both treatment selection and survival. Although propensity-
score adjusted analysis does account for the conditional prob-
ability of getting either surgery or local therapy, its power for 
controlling this selection bias is limited to the covariates avail-
able in the data set.
In addition, because SEER does not contain detailed 
enough information about tumor stage to classify all patients 
to T1a and T1b tumors, our main analysis was limited to 
the broader tumor stage of T1 tumors. Patients with T1b 
tumors are recognized as being inappropriate candidates 
for local therapy as a curative intent, so the likely inclusion 
of at least some patients who had T1b tumors in the main 
analysis could bias the results seen with local therapy.9,23,24 
However, no survival benefit for either treatment was found 
in the time-limited subgroup analysis of patients with T1a 
tumors, further supporting the promise of local therapy as an 
equivalent oncologic treatment to esophagectomy. Also, early 
2-year CSS for esophagectomy and local excisional therapy 
for patients with T1a tumors in the later years of the study 
(2004–2008) was not different. This finding suggests that 
local therapies may have been used more often in the later 
time period for patients who did not have significant comor-
bidities that put them at risk of early death because of causes 
other than esophageal cancer. Further, the small number of 
patients with T1b tumors undergoing local excisional therapy 
in the subgroup analysis limits evaluation of the impact of 
tumor depth in the main analysis. Selection bias in treatment 
of T1b tumors may at least partially explain the difference 
seen in CSS for T1a tumors versus T1 tumors, overall. Part of 
the selection bias may have arisen from the preferential use 
of local therapy for T1b tumors that were felt to be at a lower 
risk of recurrence, based on the more specific depth of sub-
mucosal invasion (sm1, sm2, sm3), which is not recorded in 
SEER. Given that local therapy is considered inadequate for 
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T1b tumors because of high risk of lymph node involvement, 
the use of local therapy rather than surgery in these patients 
also may have been because the patients were not adequate 
surgical candidates because of high risk of death as a result 
of other significant comorbid conditions. Indeed, in the SEER 
data set none of the patients treated with local therapy for T1b 
tumors died of esophageal cancer, despite an overall 3-year 
survival of less than 75% (Fig. 3B), further supporting the 
selection bias of local therapy for T1b tumors in patients who 
were likely to have short-term death from something other 
than esophageal cancer. However, future studies with larger 
groups stratified for T1a and T1b, including information on 
comorbidities, with 5-year follow-up are warranted.
In conclusion, the use of local therapy for early-stage 
superficial esophageal cancers in the SEER database has 
increased significantly over the period 1998–2008. OS after 
esophagectomy and local therapy was similar, though patients 
treated with local therapy had shorter overall follow-up and 
were more likely to die from causes other than esophageal 
cancer. The ability to generalize the results found in this study 
to other patients who may not have comorbidities associated 
with significant short-term mortality is not clear. Further 
studies most likely including multi-institutional, prospective, 
randomized controlled trials and observational studies with 
longer follow-up are needed to determine whether local ther-
apy can be used with similar long-term oncologic outcomes to 
esophagectomy in all patients.
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